
OBIO Stock Forecast & Price Target
OBIO Analyst Ratings
Bulls say
Orchestra BioMed Holdings Inc is on a positive growth trajectory, bolstered by a substantial increase in eligible patient pools due to a recent protocol update, which could enhance enrollment rates for clinical trials significantly. The company is investing heavily in research and development, with a 21% rise in R&D expenses to $14.0 million, indicating commitment to advancing its innovative therapies and strengthening its product pipeline. Additionally, the impactful clinical data recently published on AVIM therapy suggests the potential for improved patient outcomes, which could further attract strategic partnerships and drive future revenue growth.
Bears say
Orchestra BioMed Holdings Inc. has primarily operated at a loss since its establishment, raising concerns about its long-term profitability potential. The company's clinical trials may face extended timelines and escalating costs, with the risk that its product candidates might not demonstrate safety and efficacy, which could inhibit future commercialization efforts. Additionally, there is potential vulnerability regarding key intellectual property, which could jeopardize the protection of its products and limit competitive advantage.
This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
OBIO Analyst Forecast & Price Prediction
Start investing in OBIO
Order type
Buy in
Order amount
Est. shares
0 shares